Roger. Apparently RB007 is PEGylated TTP889. Regado says there have been 170 patients so far, but the P2a was only 26, so most of the data is from P1 trials. I'm less worried now -- not that I was that concerned in the first place -- this seems like a high risk, shaky program.
FWIW, here is the Regado take on why Factor IX inhibition is good idea:
Market Data 
Markets 
AI
